326 related articles for article (PubMed ID: 19235553)
1. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
[TBL] [Abstract][Full Text] [Related]
2. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
3. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
4. Corroboration of naringin effects on the intestinal absorption and pharmacokinetic behavior of candesartan cilexetil solid dispersions using in-situ rat models.
Surampalli G; K Nanjwade B; Patil PA
Drug Dev Ind Pharm; 2015; 41(7):1057-65. PubMed ID: 24918161
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.
Shaikh SM; Avachat AM
Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263
[TBL] [Abstract][Full Text] [Related]
6. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles.
Basa S; Muniyappan T; Karatgi P; Prabhu R; Pillai R
Drug Dev Ind Pharm; 2008 Nov; 34(11):1209-18. PubMed ID: 18720147
[TBL] [Abstract][Full Text] [Related]
7. Solid self-microemulsifying formulation for candesartan cilexetil.
Nekkanti V; Karatgi P; Prabhu R; Pillai R
AAPS PharmSciTech; 2010 Mar; 11(1):9-17. PubMed ID: 20013081
[TBL] [Abstract][Full Text] [Related]
8. Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state.
Ma Q; Sun H; Che E; Zheng X; Jiang T; Sun C; Wang S
Int J Pharm; 2013 Jan; 441(1-2):75-81. PubMed ID: 23266761
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
[TBL] [Abstract][Full Text] [Related]
10. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
11. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
[TBL] [Abstract][Full Text] [Related]
12. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism.
Gao F; Zhang Z; Bu H; Huang Y; Gao Z; Shen J; Zhao C; Li Y
J Control Release; 2011 Jan; 149(2):168-74. PubMed ID: 20951749
[TBL] [Abstract][Full Text] [Related]
13. Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability.
Dudhipala N; Veerabrahma K
Ther Deliv; 2017 Feb; 8(2):79-88. PubMed ID: 28088883
[TBL] [Abstract][Full Text] [Related]
14. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
15. Development of self-microemulsifying bilayer tablets for pH-independent fast release of candesartan cilexetil.
Sohn Y; Lee SY; Lee GH; Na YJ; Kim SY; Seong I; Lee BJ; Kuh HJ; Lee J
Pharmazie; 2012 Nov; 67(11):917-24. PubMed ID: 23210241
[TBL] [Abstract][Full Text] [Related]
16. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.
Zhang Z; Gao F; Bu H; Xiao J; Li Y
Nanomedicine; 2012 Jul; 8(5):740-7. PubMed ID: 21930110
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
.
Park DB; Jang K; Lee JW; Park CW; Lee BH; Kim MG; Jeon JY
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):286-294. PubMed ID: 28079517
[TBL] [Abstract][Full Text] [Related]
18. Three dimensional macroporous hydroxyapatite/chitosan foam-supported polymer micelles for enhanced oral delivery of poorly soluble drugs.
Zhang Y; Dong K; Wang F; Wang H; Wang J; Jiang Z; Diao S
Colloids Surf B Biointerfaces; 2018 Oct; 170():497-504. PubMed ID: 29960950
[TBL] [Abstract][Full Text] [Related]
19. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations.
Yuksel N; Bayindir ZS; Aksakal E; Ozcelikay AT
Int J Biol Macromol; 2016 Jan; 82():453-63. PubMed ID: 26455402
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
